A randomized controlled study of modified cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of gastric cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000036567

Enrollment

Unknown

Registered

2020-08-24

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

modified CRS + HIPEC:modified CRS

modified CRS + HIPEC:HIPEC

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Aged 18 - 75 years; 2. ECOG <= 2; 3. The expected survival time is more than 3 months; 4. Confirmed by histology as gastric adenocarcinoma, and there was no history of resection of primary or metastatic foci. 5. Limited peritoneum implantation (involving peritoneum < 2 areas); 6. PCI <= 5, ascites <= 100ml, no distant metastasis and extra regional lymph node metastasis.

Exclusion criteria

Exclusion criteria: 1. Have serious heart, lung, liver, kidney disease, can not tolerate surgery and chemotherapy; 2. Patients with perforation, obstruction and massive hemorrhage need emergency operation; 3. Clear allergy to related drugs; 4. Pregnant and lactating women; 5. Central system disorders and mental disorders that hinder the signing of informed consent and treatment compliance.

Design outcomes

Primary

Measure	Time frame
2 years OS;	—

Secondary

Measure	Time frame
time to progress;	—

Countries

China

Contacts

Public ContactHao Yuan

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

ianh76@hotmail.com+86 13621983582

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026